Subsidies & Funding

We empower medical innovation

Project Management

We manage research & innovation projects

Business Strategy

We support successful commercialisation

Cases

Ground-breaking liquid biopsy platform receives prestigious H2020 grant

ttopstart is excited to announce that Elypta, Sweden, has been granted a prestigious SME instrument phase II to help develop their liquid biopsy platform

Elypta AB. is a Swedish clinical diagnostics company aiming to drastically improve cancer diagnostics through ground-breaking science. Elypta’s mission is to prevent cancer mortality through earlier detection and closer monitoring. Throughout the past years, Elypta has been developing a novel type of liquid cancer biopsy platform – one based on metabolism. 

During project “AURORAX”, Elypta will bring their metabolism-based liquid biopsy platform for cancer diagnostics to the clinic. Elypta’s technology can detect even early-stage cancer recurrence using a combination of metabolite signature analysis and machine learning algorithms. Starting in Renal Cell Carcinoma, Elypta will validate their platform in the clinic to enable the first introduction of the technology onto the market.

Addressing a huge need for both former patients and clinicians alike, Elypta’s biopsy platform enables cost-effective and frequent patient monitoring to prevent cancer-related deaths. Fitting in with recent trends towards the development of minimally invasive cancer diagnostics, Elypta’s platform promises to provide a highly convenient, minimally invasive and cost-effective diagnostic tool to clinicians and patients.

The SME instrument phase II is the most highly sought after Horizon 2020 grant the EU has to offer to companies. Having been granted this prestigious grant, Elypta’s platform promises to be a high-potential technology amongst the vast variety of upcoming liquid biopsy platforms. It was a genuine pleasure to collaborate with Elypta on the application of this grant to make their technology a reality – we wish them the best of luck!

Contact

Jost de Bruin, MSc
+31 (0)30 73 70 779